Transparency to Alter FDA and Industry Practices - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Transparency to Alter FDA and Industry Practices
More information may be released to improve public understanding of regulatory policies.


Pharmaceutical Technology
Volume 34, Issue 7, pp. 28-34

Opening up enforcement

A more substantive and controversial Phase 2 initiative, which was published May 21, 2010, includes 21 proposals for disclosing regulatory documents and actions (posted on http://www.fda.gov/ under "transparency"). In the area of field inspections of manufacturing facilities and clinical research sites, FDA wants to list when a company is inspected and whether that site visit uncovered violations or problems requiring corrective action, or whether the entity passed inspection. FDA currently makes public only those inspection reports that raise important safety or regulatory issues. Otherwise, interested parties have to request this information through the Freedom of Information program, which can take months, if not years.

The task force received fairly broad support for regular posting of inspection reports, including from some companies that feel the information can help industry understand FDA expectations and achieve compliance. The task force suggested that inspection results may assist manufacturers and research sponsors in selecting distributors, contractors, and other business partners. A related idea is for FDA to provide summary information about common violations to enhance public understanding of its inspection practices.

Manufacturer compliance status also could be clarified by posting untitled letters on the FDA website, expanding what the agency now does with Warning Letters and with untitled letters related to biologics and drug marketing. These listings would include a company's response to the untitled letter, if the firm desires, along with the enforcement close-out notices that FDA recently began to make public. Despite concerns that posting all untitled letters could lead to information overload and the idea that untitled letters are not very useful, the task force decided that these documents can alert the public to violative practices and encourage industry compliance.

Another important change proposed in the Phase 2 document would require manufacturers to inform FDA when they initiate a product recall so that the agency can advise the public about defective, mislabeled, or potentially harmful foods or medical products. Because the agency has limited authority to remove violative items from the market, most product recalls are voluntary; companies usually inform the agency of their actions, but are not required to do so.

Providing information about a recalled product, the number of items involved, and the cause of the product defect is central to protecting public health, the task force states. At the same time, FDA wants to be able to clarify which similar products are not being recalled and when the recall (including the removal from market or destruction of affected products) has been completed, thus eliminating the potential for danger.

Implementing this type of recall notice provision may require that Congress give FDA mandatory recall authority, as proposed in food-safety legislation awaiting action on Capitol Hill. The recent massive recall of children's cold medicines by Johnson & Johnson's (New Brunswick, NJ) McNeil subsidiary has bolstered support in Congress for granting FDA recall authority over drugs and medical products, along with other enforcement powers.

Several additional transparency proposals could enhance public access to information about product safety and agency enforcement priorities. One initiative would expand the availability of adverse event reports by establishing a user-friendly system that makes it easy to search for safety reports on specific products. FDA also proposes in its Phase 2 document to publish weekly listings of high-level enforcement issues (i.e., those events that require involvement of the US Department of Justice). Posting agency work plans after five years is suggested as a way to convey FDA enforcement priorities without providing information that can help noncompliant entities avoid detection.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
21%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
8%
Regulatory compliance
42%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here